# OPTIMUM (NCT03188172)

> MUK Nine b: OPTIMUM Treatment Protocol

No report yet. It can be ordered.

- Drugs tested: daratumumab plus cyclophosphamide plus bortezomib plus lenalidomide
- Indication: high-risk multiple myeloma and plasma cell leukemia

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03188172
- Phase: PHASE2
- Status: UNKNOWN
- Sponsor: University of Leeds
- Conditions: Multiple Myeloma
- Interventions: Cyclophosphamide; Bortezomib; Lenalidomide; Daratumumab; Dexamethasone; Melphalan; Filgrastim
- Enrollment: 95
- Primary outcome: Progression free survival

## Indexed commentary on OPTIMUM so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=optimum-nct03188172